Effect of apatinib on cell proliferation, migration and apoptosis in pancreatic cancer cell line AsPC-1
- Author:
- No author available
- Journal Title:
- Chinese Journal of Pancreatology
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1674-1935.2017.01.004
- Key Word:
- 阿帕替尼;胰腺肿瘤;细胞增殖;细胞运动;细胞凋亡;Apatinib;Pancreatic neoplasms;Cell proliferation;Cell movement;Apoptosis
Abstract： Objective To investigate the effect of apatinib on the proliferation,apoptosis and migration of pancreatic cancer cell line AsPC-1 in vitro.Methods Pancreatic cancer AsPC-1 cells were treated by apatinib in different concentrations.Cell proliferation and apoptosis were measured by CCK-8 and flow cytometry,and the effect of apatinib on cell migration ability was observed by wound healing assay.Results In control and 10,20,30,40 and 50umol/L apatinib treatment group,the inhibitory rates of AsPC-1 cells were 0,(1.45 ±0.68)％,(16.92±0.70)％,(23.84±0.84)％,(34.35±1.55)％ and (37.33± 0.81) ％,respectively.Cell proliferation was obviously inhibited by apatinib as the concentration increased,and the differences were statistically significant (P ＜ 0.05).In control and 20,40 umol/L apatinib treatment group,the apoptotic rates were (9.44 ± 0.18) ％,(16.62 ± 0.19) ％ and (25.42 ± 0.41) ％,respectively.Number of apoptotic cells was obviously increased by apatinib as the concentration increased,and the differences were statistically significant (P ＜ 0.05).In control and 20,40 umol/L apatinib treatment group,the migration ability was (29.5 ± 0.7) ％,(17.4 ± 0.9) ％ and (6.6 ± 0.5) ％,which was greatly decreased as the concentration increased,and the differences were statistically significant (P ＜ 0.05).Conclusions Apatinib can effectively inhibit the proliferation and migration of pancreatic cancer AsPC-1 cells and induce apoptosis.
- [1]张太平,曹喆,赵玉沛.胰腺癌的化疗与放疗[J].2015,(8).
- [2]赵玉沛.外科医师要重视胰腺癌的临床研究[J].2016,(6).
- [3]R, Longo,G, Gasparini.Challenges for patient selection with VEGF inhibitors.[J].2007,60(2).
- [4]Xie C,Guo H,Xu Y,etc.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.[J].2011,102(7).
- [5]J, Folkman.Angiogenesis in cancer, vascular, rheumatoid and other disease.[J].1995,1(1).
- [6]Hong, Peng,Qiuyang, Zhang,Jiali, Li,etc.Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.[J].2016.
- [7]Hidalgo M.Pancreatic cancer.[J].2010,362(17).
- [8]Haijun, Zhang.Apatinib for molecular targeted therapy in tumor.[J].2015,9.
- [9]Komoto,M.,Kato,Y.,Doi,Y.,etc.Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer[J].2010,101(6).
- [10]Hu,X.,Zhang,J.,Xu,B.,etc.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].2014,135(8).
- [11]H A, Burris,M J, Moore,J, Andersen,etc.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.[J].1997,15(6).
- [12]Doi,Y.,Yashiro,M.,Yamada,N.,etc.VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells[J].2012,19(8).
- [13]Roviello, Giandomenico,Ravelli, Andrea,Polom, Karol,etc.Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].2016,372(2).
- [14]Hwang J,Bergsland EK,Ko AH,etc.A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?[J].2008,26(5).